{"Drugs":{"Drug":{"Id":47197,"DrugType":{"Type":"Biological therapeutic"},"DrugTargetMaturity":{"TargetIndication":{"IndicationId":651,"IndicationName":"Cancer","MinPatentApplicationDate":"2012-11-19T00:00:00Z","TargetId":"GTGT-03445","TargetName":"BIRC4 gene"}},"DevelopmentStatusCurrent":{"Row":[{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"49","$":"Breast tumor"},"StatusDate":"2009-01-12T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1086058"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1262","$":"Non-small-cell lung cancer"},"StatusDate":"2009-07-15T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1086139"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"1731","$":"Acute myelogenous leukemia"},"StatusDate":"2011-06-13T00:00:00Z"},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"1731","$":"Acute myelogenous leukemia"},"StatusDate":"2011-06-13T00:00:00Z"},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-10-12T00:00:00Z"},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"1767","$":"Hepatocellular carcinoma"},"StatusDate":"2012-07-03T00:00:00Z"},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"203","$":"Lymphoma"},"StatusDate":"2011-10-12T00:00:00Z"},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"249","$":"Pancreas tumor"},"StatusDate":"2011-05-31T00:00:00Z"},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"725","$":"Solid tumor"},"StatusDate":"2010-02-13T00:00:00Z"},{"Company":{"@id":"17006","$":"Idera Pharmaceuticals Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"651","$":"Cancer"},"StatusDate":"2002-09-17T00:00:00Z","SourceLink":{"@type":"PR","@id":"464176"}}]},"DevelopmentStatusHistoric":{"Row":[{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1731","$":"Acute myelogenous leukemia"},"StatusDate":"2009-11-19T00:00:00Z","SourceLink":{"@type":"PR","@id":"1058669"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1731","$":"Acute myelogenous leukemia"},"StatusDate":"2005-10-31T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"635647"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"49","$":"Breast tumor"},"StatusDate":"2007-09-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"835850"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2008-07-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"930244"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1767","$":"Hepatocellular carcinoma"},"StatusDate":"2009-03-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1038802"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"203","$":"Lymphoma"},"StatusDate":"2008-07-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"930244"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1262","$":"Non-small-cell lung cancer"},"StatusDate":"2007-09-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"835850"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"249","$":"Pancreas tumor"},"StatusDate":"2007-09-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"835850"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"651","$":"Cancer"},"StatusDate":"2006-09-21T00:00:00Z","SourceLink":{"@type":"PR","@id":"624351"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"XD","$":"North America"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"651","$":"Cancer"},"StatusDate":"2005-07-06T00:00:00Z","SourceLink":{"@type":"PR","@id":"611225"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"651","$":"Cancer"},"StatusDate":"2004-03-29T00:00:00Z","SourceLink":{"@type":"PR","@id":"529304"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"725","$":"Solid tumor"},"StatusDate":"2006-06-30T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"803200"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"651","$":"Cancer"},"StatusDate":"2002-09-17T00:00:00Z","SourceLink":{"@type":"PR","@id":"464176"}},{"Company":{"@id":"25069","$":"Aegera Therapeutics Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"203","$":"Lymphoma"},"StatusDate":"2008-06-03T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"912589"}}]}}}}